Corxel Deal Deck Adds CX11/CX12 Data and 2027 Milestone Timeline
AMAN is trading near its 52-week low of $9.98 (1.5% above the low).
Summary
Corxel's November 9 investor deck for its merger with Amanat lays out detailed CX11 obesity data and a 2027 Phase 3/IND timeline, adding clinical substance to the already-announced $200 million deal and $300 million PIPE.
Key Events · M&A and Partnerships · AMAN
-
Investor Deck Details CX11 Obesity Data
CX11 showed 10.3%-11.5% weight loss at Week 36 in U.S. Phase 2 and 12.2%-12.4% at Week 52 in China Phase 3, benchmarked against Foundayo's 12.4% at 72 weeks.
-
Phase 3 and NDA Timeline Set
Global Phase 3 initiation is targeted for Q1 2027, with NDA submissions by 2029 and launch expected 2030-31; IP exclusivity runs to 2041 via composition-of-matter and 2044 via polymorph patents.
-
CX12 Preclinical With 2027 IND
Oral amylin candidate CXL1125 showed ~11%-13% body weight reduction in diet-induced obese rats, comparable to injectable eloralintide; IND submission is planned for 1H 2027.
-
Deal Terms Unchanged From October
The definitive BCA was signed October 25, 2026 at a $200 million implied equity value, with a $300 million PIPE and expected closing in H1 2027.
Analysis · AMAN · Real Estate & Construction
The clinical substance behind the valuation is what matters here, not the deal terms. This 425 carries the investor deck Corxel presented on November 9, 2026 for its merger with Amanat, but the transaction itself was already public: a definitive BCA signed October 25, 2026 at a $200 million implied equity value with a $300 million PIPE. What the deck adds is the data. CX11 showed 10.3%-11.5% weight loss at Week 36 in U.S. Phase 2 and 12.2%-12.4% at Week 52 in China Phase 3, with global Phase 3 targeted for Q1 2027 and NDA submissions by 2029. CX12, an oral amylin candidate, remains preclinical with an IND planned for 1H 2027. For SPAC holders, this is the first detailed look at whether the merged company's pipeline justifies the price — and the answer hinges on Phase 3 execution over the next two years, not on anything in this deck.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMAN was trading at $10.13 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $100.9M. The 52-week trading range was $9.98 to $10.79. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.